Secarna Pharmaceuticals announced that the Company has entered into an research agreement with a global pharmaceutical company to support research and discovery in the field of oncology.
- Secarna to provide leading industry partner with LNAplusTM based antisense oligonucleotides to support research and development in the field of oncology
- First research agreement with large global pharmaceutical company follows several successful collaborations with specialty pharmaceutical and biotech players in 2018
Munich/Martinsried, Germany, September 10, 2019 – Secarna Pharmaceuticals (“Secarna”), a new breed of biopharmaceutical company focusing on the discovery and development of antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets, today announced that the Company has entered into an research agreement with a global pharmaceutical company to support research and discovery in the field of oncology. Under the terms of the agreement, the global top 10 pharmaceutical partner will utilize ASOs derived from Secarna’s proprietary LNAplus™ platform in support of anti-cancer therapies the partner is developing and commercializing. Financial terms and the name of the partner were not disclosed. The LNAplus™ platform has been validated through numerous internal projects as well as multiple academic and industry collaborations such as with Firebrand Therapeutics, Lipigon Pharmaceuticals, and Met P Pharma.
“This first agreement with a large global pharmaceutical partner is a major milestone for Secarna and a crucial step in paving the path for a new generation of anti-cancer therapeutics,” said Jonas Renz, Managing Director and Co-founder of Secarna Pharmaceuticals. “The agreement is a further testament to our LNAplusTM approach of developing highly specific, safety-optimized and efficacious antisense oligonucleotide therapies for challenging targets.”
About Secarna’s Proprietary Drug Discovery Platform, LNAplus™
Secarna’s proprietary third-generation antisense oligonucleotide (ASO) platform, LNAplusTM, which encompasses all aspects of drug discovery and pre-clinical development, enables the Company to discover novel antisense-based therapies for challenging or currently undruggable targets. Secarna’s platform and ASOs have previously been validated by numerous in-house projects as well as in several academic and industry collaborations. With over 15 development programs focusing on targets and indications such as immuno-oncology, immunology, antiviral, fibrotic diseases, ophthalmology, neurodegenerative diseases and cardiometabolic diseases, where antisense-based approaches have clear benefits compared to other therapeutic modalities, Secarna is the leading European antisense drug discovery and development company.
About Secarna Pharmaceuticals GmbH & Co. KG
Secarna Pharmaceuticals is the next generation antisense oligonucleotide (ASO) company with multiple innovative antisense therapies in various stages of pre-clinical development in the areas of immuno-oncology, ophthalmology, immunology, fibrotic diseases (airways, liver, kidney), and anti-viral applications. Secarna’s mission is to maximize the performance and output of its proprietary LNAplus™ antisense oligonucleotide platform to develop highly specific, safe, and efficacious antisense therapies for challenging or currently not druggable targets. www.secarna.com
Contact
Jonas Renz
Managing Director and Co-founder
Jonas.Renz@secarna.com
Secarna Pharmaceuticals GmbH & Co. KG
Am Klopferspitz 19
82152 Planegg/Martinsried
Tel.: +49 (0)89 215 46 375
- End of Press Release -
Should you have any questions or would like to receive further information, please do not hesitate to contact us.
Best regards
For media enquiries:
Anne Hennecke
MC Services AG
anne.hennecke@mc-services.eu
Tel.: +49 (0)211.52 92 52 22
